Dr. Jordan Berlin, MD
Claim this profileVanderbilt-Ingram Cancer Center
Studies Solid Tumors
Studies Cancer
13 reported clinical trials
21 drugs studied
Area of expertise
1Solid Tumors
Stage IV
HER2 positive
Stage III
2Cancer
Stage IV
HER2 positive
Stage III
Affiliated Hospitals
Clinical Trials Jordan Berlin, MD is currently running
BMS-986340 + Nivolumab/Docetaxel
for Cancer
This trial tests a new drug, BMS-986340, alone and with other cancer treatments (nivolumab and docetaxel) in patients with advanced solid tumors. The goal is to find out if it is safe and effective in treating these cancers.
Recruiting1 award Phase 1 & 26 criteria
TOS-358
for Cancer
This trial tests TOS-358, a new drug for adults with specific cancers that have a genetic mutation. It aims to find the safest dose and see how well patients tolerate it. The drug works by blocking a gene that helps cancer cells grow.
Recruiting1 award Phase 1
More about Jordan Berlin, MD
Clinical Trial Related8 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jordan Berlin, MD has experience with
- Nivolumab
- Docetaxel
- SM08502
- Nab Paclitaxel
- DF1001
- Trifluridine/Tipiracil
Breakdown of trials Jordan Berlin, MD has run
Solid Tumors
Cancer
Colorectal Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Jordan Berlin, MD specialize in?
Is Jordan Berlin, MD currently recruiting for clinical trials?
Are there any treatments that Jordan Berlin, MD has studied deeply?
What is the best way to schedule an appointment with Jordan Berlin, MD?
What is the office address of Jordan Berlin, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.